Additionally, several drugs targeting epigenetic changes, such as BCL-2 inhibitors, CHK inhibitors, PLK inhibitors, AURK inhibitors, and EZH2 inhibitors, are being considered for treating transformed SCLC, based on its lineage plasticity during the transformation from EGFR-mutant NSCLC. The gene discussed is PLK1; the disease is non-small cell lung carcinoma.